BridgeMD
New treatment option for Subdural Hematoma
Official title Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)
ClinicalTrials.gov ID: NCT04923984
What this study is testing
- What it's testing
- EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH. Hypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- \- All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic.
You likely can't join if
- If informed consent cannot be obtained from the patient or their substitute decision maker.
- Known allergy to liquid embolic agent
The study team makes the final eligibility decision.
Where it's taking place
- Winnipeg MB, Manitoba, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Winnipeg MB, Manitoba, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.